BioStock: Strong start to 2022 for Respiratorius

Report this content

2022 looks to be an eventful year for Lund-based Respiratorius, which released its report for the fourth quarter on Tuesday. The company has started the PK study with the new formulation of VAL001, while announcing a new capital injection and plans to spin off its respiratory project. BioStock contacted the company's CEO Johan Drott to dig a little deeper into the quarterly report and get his view on the interesting situation the company is in at the moment. 

Read the full interview with Johan Drott at

This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links

Quick facts

BioStock: Strong start to 2022 for Respiratorius
Tweet this